| Funding Opportunity ID: |
322578 |
| Opportunity Number: |
CDC-RFA-PS20-2009 |
| Opportunity Title: |
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.270 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments |
| Additional Information on Eligibility: |
State governments or their bona fide agents (includes the District of Columbia) Local governments or their bona fide agents |
| Agency Code: |
HHS-CDC-NCHHSTP |
| Agency Name: |
Department of Health and Human Services
Centers for Disease Control – NCHHSTP |
| Posted Date: |
Mar 11, 2020 |
| Close Date: |
May 11, 2020 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date. |
| Last Updated Date: |
Mar 11, 2020 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
$341,020,000 |
| Expected Number of Awards: |
58 |
| Description: |
This NOFO supports integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Applicants should develop a jurisdictional viral hepatitis elimination plan, promote comprehensive hepatitis B and C reporting, improve HBV and HCV testing policies, and increase healthcare providers trained to treat hepatitis B and C. Contingent on funding, the following activities can be supported: surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics); and increased access to services preventing viral hepatitis and other bloodborne infections among persons who inject drugs (PWID). Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of hepatitis B, C and HIV among PWID in jurisdictions disproportionately affected by high-risk drug use. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk. |
| Version: |
1 |
|
